The Pulmonary Hypertension Association (PHA) will host the inaugural Northern Virginia Walk on Saturday, May 4, in Alexandria, Va. The walk offers an opportunity for patients, caregivers, friends, family and medical professionals to gather for a common goal: raising funds to help support those affected by pulmonary hypertension (PH) and ultimately find a cure.
“Luckily, some friends directed me to the PH Association website… That restored my hope!” "Hi. My name is Christa and in May 2010, I was diagnosed with idiopathic pulmonary arterial hypertension (PAH). "On May 19, 2010, I had an appointment to see the doctor. There is a free/by income clinic downtown. I
The Pulmonary Hypertension Association (PHA) is pleased to announce the launch of its new Clinical Trial Finder, now available in the research section of the PHA website, PHAssociation.org. PHA provides this tool to help participants learn more about ongoing PH research. The tool includes filters to narrow search results to fit an individual’s personal needs.
The Pulmonary Hypertension Association (PHA) is pleased to join The National Blood Clot Alliance and other health care organizations around the nation to spread the word about blood clots during Blood Clot Awareness Month (BCAM) in March. This year’s theme is “Together We Can Increase Awareness and Save Lives.” BCAM’s goal is to bring
“I am extremely glad I have friends and family that are helping me through this process, no one should do this alone.” “I am 21-year-old college student studying to be a Physician Assistant and I was diagnosed with Pulmonary Arterial Hypertension (PAH) on Jan. 17, 2019. I was over all completely healthy
“When the pulmonology team met with my husband and me and tried to explain CTEPH, I simply broke down.” “I am 57 years old and was diagnosed last November at the University of Kansas (KU MED) Hospital in Kansas City with CTEPH after a large blood clot was found in my right
A team of researchers has increased the accuracy of a tool used to predict survival for individuals with World Health Organization Group 1 PH (pulmonary arterial hypertension or PAH). CHEST Journal, the official publication of the American College of Chest Physicians, has published a study by Raymond L. Benza, M.D., a cardiologist at Allegheny
Questions to Consider When Choosing Between Brand and Generic Therapy Teva Pharmaceutical Industries recently announced the launch of ALYQ ™ (tadalafil), a generic version of the drug Adcirca®. Mylan launched the first generic tadalafil in August. How an individual with pulmonary hypertension (PH) is impacted by the availability of generic therapy may depend on
“Rare Disease Day is not just about PH; it is also a recognition of the many rare diseases for which resources and funding are often limited.” By Shan Hardwick “I have PH, caused by scleroderma. I had symptoms of a scleroderma-related syndrome for years, but no one put them together for a
